Abstract:RET fusion has emerged as a targetable oncogenic driver in non-small cell lung cancer. The optimal methods to identify actionable RET fusions during clinical practice remain to be evaluated. Herein, we performed a comparative analysis on RET fusions using targeted next-generation sequencing at DNA (DNA-seq) and RNA (RNA-seq) levels. A total of 53 lung adenocarcinoma patients harboring non-canonical RET fusions identified by DNA-seq were selected to receive RNA-seq of their remaining tumor samples using a 115-cancer gene panel (OncoRNA). Of them, 43 passed quality control of RNA-seq. The breakpoints and partners of RET-fusion identified by DNA- and RNA-Seq were described and compared. Of the 43 patients, DNA-seq identified 25 patients with concurrent 5’ RET fusions and 3’ canonical RET fusions (KIF5B-RET (K15:R12) or CCDC6-RET (C1:R12), subgroup A), 2 patients with 5’ RET fusions alone (subgroup B), 8 patients with frameshift or out-of-frame fusions (subgroup C) and 8 patients with 3’ non-canonical RET fusions alone (subgroup D). In total, 40 of 43 patients (93%) were positive for RET-fusions at RNA level. In subgroup A, RNA-seq detected all canonical RET-fusions with identical breakpoints to DNA-seq, while no transcripts of the 5’ RET fusions were detected. Patients in subgroups B and C did not have in-frame actionable fusions detected by DNA-seq. However, in subgroup B, RNA-seq identified 1 KIF5B-RET transcript with rare breakpoint (K24:R10). In subgroup C, only 1 patient was negative while 7 patients were positive at RNA level including 6 with canonical RET fusions of which the RET breakpoints were identical to DNA-seq. The discordance might be explained by complex DNA structural rearrangements and RNA splicing. In subgroup D, RNA-seq identified 7 of 8 patients with RET fusions concordant with DNA-seq, and 1 patient was negative. Most RET fusions in this subgroup involved rare partners including KIAA1468, LMNA, TRIM33, EDC4, ANKRD26, and AKAP13. DNA-seq and RNA-seq showed high consistency in detecting RET fusions. RNA-seq could be valuable in determining the actionability of 5’ or frameshift/out-of-frame DNA fusions.

Supplementary Table 4 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 5 and 6 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 5 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Figure 1 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Data from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of NSCLC

Incidence of FGFR-TACC Gene Fusions in Chinese Non-Small Cell Lung Cancer (NSCLC): A Multicenter Study.

Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Clinical Significances of FGFR Fusion for the Lung Squamous Cell Carcinoma and Adenocarcinoma

1148P Identification and Validation of RET Fusions in Lung Adenocarcinoma Through DNA and RNA Sequencing

Supplementary Table 3 from TGFBR1 Haplotypes and Risk of Non–Small-Cell Lung Cancer

FGFR1 Amplification and FGFR Gene Fusion in Resected Squamous Cell Carcinoma of the Lung

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.

Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing

P2.03-09 the Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study

Table S4 from Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).